Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991 Oct 01;68(7):1536-7
Date
10/01/1991Pubmed ID
1893353DOI
10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-bScopus ID
2-s2.0-0026349435 (requires institutional sign-in at Scopus site) 116 CitationsAbstract
A 19-year-old man with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha (IFN-alpha) therapy for 45 months had systemic lupus erythematosus disease features: malar rash, migratory arthralgias, elevated antinuclear antibodies, elevated antinative DNA, hypocomplementemia, lymphopenia, and proteinuria. After discontinuation of the IFN and initiation of corticosteroids, there was gradual recovery of symptoms, a decline in antinative DNA and antinuclear antibodies to normal levels, and a decrease in proteinuria. The potential association between IFN therapy and the development of systemic lupus erythematosus, and the role of IFN in other autoimmune diseases, is discussed.
Author List
Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz MAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntineoplastic Combined Chemotherapy Protocols
Humans
Interferon Type I
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lupus Erythematosus, Systemic
Male
Recombinant Proteins
Remission Induction
